TY - JOUR
T1 - Chronic demodicosis in patients with immune dysregulation
T2 - An unexpected infectious manifestation of Signal transducer and activator of transcription (STAT)1 gain-of-function
AU - Shamriz, Oded
AU - Lev, Atar
AU - Simon, Amos J.
AU - Barel, Ortal
AU - Javasky, Elisheva
AU - Matza-Porges, Sigal
AU - Shaulov, Adir
AU - Davidovics, Zev
AU - Toker, Ori
AU - Somech, Raz
AU - Zlotogorski, Abraham
AU - Molho-Pessach, Vered
AU - Tal, Yuval
N1 - Publisher Copyright:
© 2021 British Society for Immunology
PY - 2021/10
Y1 - 2021/10
N2 - Signal transducer and activator of transcription (STAT)1 heterozygous gain-of-function (GOF) mutations are known to induce immune dysregulation and chronic mucocutaneous candidiasis (CMCC). Previous reports suggest an association between demodicosis and STAT1 GOF. However, immune characterization of these patients is lacking. Here, we present a retrospective analysis of patients with immune dysregulation and STAT1 GOF who presented with facial and ocular demodicosis. In-depth immune phenotyping and functional studies were used to characterize the patients. We identified five patients (three males) from two non-consanguineous Jewish families. The mean age at presentation was 11.11 (range = 0.58–24) years. Clinical presentation included CMCC, chronic demodicosis and immune dysregulation in all patients. Whole-exome and Sanger sequencing revealed a novel heterozygous c.1386C>A; p.S462R STAT1 GOF mutation in four of the five patients. Immunophenotyping demonstrated increased phosphorylated signal transducer and activator of transcription in response to interferon-α stimuli in all patients. The patients also exhibited decreased T cell proliferation capacity and low counts of interleukin-17-producing T cells, as well as low forkhead box protein 3+ regulatory T cells. Specific antibody deficiency was noted in one patient. Treatment for demodicosis included topical ivermectin and metronidazole. Demodicosis may indicate an underlying primary immune deficiency and can be found in patients with STAT1 GOF. Thus, the management of patients with chronic demodicosis should include an immunogenetic evaluation.
AB - Signal transducer and activator of transcription (STAT)1 heterozygous gain-of-function (GOF) mutations are known to induce immune dysregulation and chronic mucocutaneous candidiasis (CMCC). Previous reports suggest an association between demodicosis and STAT1 GOF. However, immune characterization of these patients is lacking. Here, we present a retrospective analysis of patients with immune dysregulation and STAT1 GOF who presented with facial and ocular demodicosis. In-depth immune phenotyping and functional studies were used to characterize the patients. We identified five patients (three males) from two non-consanguineous Jewish families. The mean age at presentation was 11.11 (range = 0.58–24) years. Clinical presentation included CMCC, chronic demodicosis and immune dysregulation in all patients. Whole-exome and Sanger sequencing revealed a novel heterozygous c.1386C>A; p.S462R STAT1 GOF mutation in four of the five patients. Immunophenotyping demonstrated increased phosphorylated signal transducer and activator of transcription in response to interferon-α stimuli in all patients. The patients also exhibited decreased T cell proliferation capacity and low counts of interleukin-17-producing T cells, as well as low forkhead box protein 3+ regulatory T cells. Specific antibody deficiency was noted in one patient. Treatment for demodicosis included topical ivermectin and metronidazole. Demodicosis may indicate an underlying primary immune deficiency and can be found in patients with STAT1 GOF. Thus, the management of patients with chronic demodicosis should include an immunogenetic evaluation.
KW - demodex
KW - demodicosis
KW - gain-of-function
KW - immune dysregulation
KW - STAT-1
UR - http://www.scopus.com/inward/record.url?scp=85109632621&partnerID=8YFLogxK
U2 - 10.1111/cei.13636
DO - 10.1111/cei.13636
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34114647
AN - SCOPUS:85109632621
SN - 0009-9104
VL - 206
SP - 56
EP - 67
JO - Clinical and Experimental Immunology
JF - Clinical and Experimental Immunology
IS - 1
ER -